SEC-sourced researchBeta
CTMX
CytomX Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001501989
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Mar 16, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 138,103,000.0000 | Mar 16, 2026 |
| December 2025 | 76,201,000.0000 | Mar 16, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 76,201,000.0000 | -17,368,000.0000 | -75,587,000.0000 | 151,566,000.0000 | 52,558,000.0000 | Mar 16, 2026 |
| December 2024 | 138,103,000.0000 | 31,869,000.0000 | -86,231,000.0000 | 120,533,000.0000 | 120,989,000.0000 | Mar 16, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $76.2M | December 2025 | Mar 16, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $138.1M | December 2024 | Mar 16, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$17.37M | December 2025 | Mar 16, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$75.59M | December 2025 | Mar 16, 2026 | 10-K |
| Total assetsAssets | $151.57M | December 2025 | Mar 16, 2026 | 10-K |
| Total liabilitiesLiabilities | $52.56M | December 2025 | Mar 16, 2026 | 10-K |